38396-89-3

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-3'-ACETYLOXYLACETOPHENONE is used as a research compound for the preparation of substituted heterocycle compounds. These heterocycle compounds are of interest due to their potential to enhance the antitumor activity of other cytotoxic agents, making them valuable in the development of new cancer treatments.
In the study of preparation of substituted heterocycle compounds, 2-BROMO-3'-ACETYLOXYLACETOPHENONE serves as a key intermediate, allowing researchers to explore the synthesis of novel compounds with improved therapeutic properties. This can lead to the discovery of more effective cancer therapies with fewer side effects, ultimately benefiting patients and advancing the field of oncology.

Upstream product

• 2454-35-5 3-acetylphenyl acetate 
• 7732-18-5 water 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 26031-56-1 1-(3-hydroxy-phenacyl)-pyridinium; bromide 
• 857618-76-9 2-acetoxy-1-(3-acetoxy-phenyl)-ethanone 
• 22510-12-9 2-ethylamino-1-(3-hydroxy-phenyl)-ethanone 
• 709-55-7 etilefrine 
• 53515-92-7 1-(3-hydroxy-phenyl)-2-piperidin-1-yl-ethanol 
• 26031-89-0 1-(3,β-dihydroxy-phenethyl)-pyridinium; bromide 
• 1477503-56-2 1-(3-(6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenoxy)propan-2-one 
• 907961-67-5 C₁₄H₉F₃N₂O 
• 1314747-02-8 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenol 
• 1477503-57-3 3-(6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenyl methanesulfonate 
• 1477503-58-4 3-(6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenyl 4-methylbenzenesulfonate 
• 1477503-60-8 1-(3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenoxy)propan-2-one 
• 1477503-61-9 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenyl methanesulfonate 

Relevant academic research and scientific papers

Efficient synthesis of (R)-phenylephrine using a polymer-supported Corey-Bakshi-Shibata catalyst

An efficient and mild synthetic route to (R)-phenylephrine hydrochloride using Corey-Bakshi-Shibata (CBS) catalyst was reported. In order to avoid a lengthy recovery process of the catalyst from homogeneous reaction, a polymer-supported CBS catalyst was prepared, and a preliminary attempt was made to achieve a continuous reduction on a laboratory scale, which contributes to synthesis of (R)-phenylephrine in a cost-effective way.

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists

In this study, a series of fused-heterocyclic derivatives were systematically designed and synthesized using an efficient route, and evaluated in terms of GLP-1R agonist activity. We employed short synthetic steps and reactions that are tolerant of the presence of various functional groups and suitable for parallel operations to enable the rapid generation of libraries of diverse and structurally complex small molecules. Of the compounds synthesized, 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a] pyridin-2-yl)phenyl methanesulfonate (8e) was the most potent agonist with an EC50 of 7.89 μM, and thus is the compound with the greatest potential for application. These findings represent a valuable starting point for the design and discovery of small-molecule GLP-1R agonists that can be administered orally.

Compounds enhancing antitumor activity of other cytotoxic agents

This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).